Combination treatments in Alzheimer's disease: risks and benefits (Q37737293)

22 August 2017

1 reference

title

Combination treatments in Alzheimer's disease: risks and benefits (English)

1 reference

22 August 2017

0 references

1

Tomasz Sobow

1 reference

22 August 2017

1 May 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

5

1 reference

22 August 2017

693-702

1 reference

Current concepts in Alzheimer's disease: a multidisciplinary review

22 August 2017

1 reference

Dementia of the Alzheimer type

21 January 2018

1 reference

Therapeutic options in Alzheimer's disease

21 January 2018

1 reference

Cholinesterase inhibitors and beyond

21 January 2018

1 reference

Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease

21 January 2018

1 reference

Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease

21 January 2018

1 reference

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

21 January 2018

1 reference

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

21 January 2018

1 reference

Cholinesterase inhibition: is there evidence for disease-modifying effects?

21 January 2018

1 reference

Memantine combined with an acetyl cholinesterase inhibitor - hope for the future?

21 January 2018

1 reference

Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients.

21 January 2018

1 reference

Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers

21 January 2018

1 reference

Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey.

21 January 2018

1 reference

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

21 January 2018

1 reference

Metabotropic glutamate and muscarinic cholinergic receptor-mediated preferential inhibition of N-methyl-D-aspartate component of transmissions in rat ventral tegmental area

21 January 2018

1 reference

Cholinergic direct inhibition of N-methyl-D aspartate receptor-mediated currents in the rat neocortex

21 January 2018

1 reference

Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease

21 January 2018

1 reference

Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons

21 January 2018

1 reference

Pharmacodynamics of memantine: an update

21 January 2018

1 reference

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

21 January 2018

1 reference

Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects

21 January 2018

1 reference

Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study

21 January 2018

1 reference

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

21 January 2018

1 reference

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

21 January 2018

1 reference

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

21 January 2018

1 reference

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

21 January 2018

1 reference

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

21 January 2018

1 reference

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

The role of nutrition in Alzheimer's disease: epidemiological evidence

21 January 2018

1 reference

Adherence to a Mediterranean diet, cognitive decline, and risk of dementia

21 January 2018

1 reference

Physical activity, diet, and risk of Alzheimer disease

21 January 2018

1 reference

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

Donepezil plus vitamin E as a treatment in Alzheimer disease

21 January 2018

1 reference

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

21 January 2018

1 reference

Vitamin E use is associated with improved survival in an Alzheimer's disease cohort

21 January 2018

1 reference

A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

21 January 2018

1 reference

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

21 January 2018

1 reference

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

21 January 2018

1 reference

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

Alternative medicine and Alzheimer disease

21 January 2018

1 reference

The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil

21 January 2018

1 reference

Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.

21 January 2018

1 reference

NSAIDs for the Chemoprevention of Alzheimer’s Disease

21 January 2018

1 reference

Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease

21 January 2018

1 reference

Therapeutic potential of statins in Alzheimer's disease.

21 January 2018

1 reference

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease

21 January 2018

1 reference

No additional benefit of HRT on response to rivastigmine in menopausal women with AD.

21 January 2018

1 reference

Re-assessing the relationship between cholesterol, statins and Alzheimer's disease

21 January 2018

1 reference

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

21 January 2018

1 reference

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

21 January 2018

1 reference

Biochemical markers and risk factors of Alzheimer's disease

21 January 2018

1 reference

Defining and labeling disease-modifying treatments for Alzheimer's disease.

21 January 2018

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

Biomarkers in brain disease. Preface.

21 January 2018

1 reference

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

21 January 2018

1 reference

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

21 January 2018

1 reference

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.10.43

1 reference

22 August 2017

1 reference

PubMed ID

20420490